Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

imipenem-cilastatin-relebactam

A parenteral antibiotic preparation containing imipenem, cilastatin sodium and relebactam, with bactericidal activity. Imipenem, a broad spectrum beta-lactam carbapenem antibiotic, binds to and inactivates penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium, a renal dehydropeptidase inhibitor, reduces the breakdown of imipenem by renal dehydropeptidase. Relebactam, a beta-lactamase inhibitor, reduces the breakdown of imipenem by certain serine beta-lactamases among gram-negative bacteria. Imipenem is active against a wide range of gram-positive and gram-negative organisms, and the imipenem, cilastatin sodium and relebactam combination may be used to treat infections caused by resistant gram-negative bacteria.
Synonym:imipenem/cilastatin sodium/relebactam
US brand name:Recarbrio
Search NCI's Drug Dictionary